Aurora has begun delivering goods with fully driverless trucks between Dallas and Houston, making them the first company with a commercial autonomous trucking service on public roads. The trucks are equipped with sensors that can see over four football fields away.
Mati Carbon receives the main prize of 50 million dollars in the XPRIZE Carbon Removal competition. The company uses crushed basalt on agricultural land to accelerate a natural weathering process that permanently binds carbon dioxide, while improving soil quality for small-scale farmers.
A medication approved for rare genetic diseases, proves to kill malaria-carrying mosquitoes when they suck blood from people who have taken the medicine. The mosquitoes die within 24 hours after sucking blood containing nitisinone, which is faster than with previously tested medications.
Digital technology reduces the risk of cognitive impairment by 58 percent according to a comprehensive meta-analysis. The effect persisted even after accounting for demographic factors, socioeconomic status, and health conditions.
British company Pulsar Fusion is developing Sunbird, a fusion-powered spacecraft that can reach speeds up to 805,000 kilometers per hour. Nuclear fusion in space may be easier to achieve than on Earth, as vacuum is a more natural environment for the fusion process.
Dartmouth researchers report a 51 percent reduction in depression symptoms in patients who used the AI chatbot Therabot. The study shows that patients developed trust in the chatbot comparable to relationships with human therapists.
Bill Gates has decided to donate virtually his entire fortune through the Gates Foundation. During the foundation's first 25 years, over 100 billion dollars were donated, and Gates plans to double this amount to more than 200 billion dollars by 2045.
The percentage of university students with symptoms of depression has decreased from 44 percent in 2022 to 38 percent in 2024. Studies show that this trend applies to American youth in general, with decreasing rates of depression and suicide.
A clinical trial showed that the drug lenacapavir protected 100 percent of women and girls against HIV infection. The drug only needs to be injected twice a year to provide full protection. New results suggest that an annual injection may be sufficient for long-lasting protection.